biotech insider buying

biotech insider buying Articles

The most notable insider purchases of stock in the past week were in biotech and energy companies, as well as a specialty retailer.
The past week brought some huge insider share purchases, including a contrarian buy at an e-commerce platform operator and another at a troubled satellite provider.
Warren Buffett again boosted his stake in the newly independent Sirius XM. A biotech IPO prompted huge insider buying as well.
Warren Buffett again boosted his stake in the newly independent Sirius XM. Biotech stocks continue to prompt notable insider buying as well.
Warren Buffett recently boosted his stake in the newly independent Sirius XM. Biotech initial public offerings in the past week also prompted some huge insider buying.
Public offerings of stock and activist investor activity prompted some huge insider buying at an entertainment company, an airline, biotechs, and more.
A public offering of shares this past week prompted a huge purchase from a beneficial owner. Meanwhile, a couple of repeat buyers further boosted their stakes as well.
IPOs at three biotechs last week tempted insiders to make huge purchases of shares. This effect spilled over into buying at a couple of other biotechs as well.
Though insider buying has slowed to a trickle in the past two weeks, two CEOs and two beneficial owners made notable purchases.
Top carmaker Stellantis boosted its stake in an aircraft maker last week, and biotech and energy stocks saw notable insider buying too.
A renowned billionaire investor, a French energy giant, and other insiders were scooping up shares of these five stocks as the second quarter began.
Warren Buffett boosts his stake in this tracking stock again, plus notable insider buying from an NFL team owner and a new CEO.
Public offerings of stock tempted some insider buying, and one insider stepped up to support a struggling online delivery service provider.
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.